1. Introduction {#sec1-cancers-12-00362}
===============

Soft tissue sarcomas are a heterogeneous group of rare, solid malignancies with a mesenchymal origin. They account for approximately 1% of all adult malignancies with an incidence rate of 6 per 100,000 inhabitants \[[@B1-cancers-12-00362],[@B2-cancers-12-00362]\]. Soft tissue sarcomas (STS) comprise a group of more than 50 different histologic subtypes that differ in their oncological behavior and outcome \[[@B3-cancers-12-00362]\]. Due to their rarity and heterogeneity, most studies regarding treatment outcomes in STS include all subtypes rather than focusing on specific subtypes. Undifferentiated pleomorphic sarcomas (UPS), previously termed malignant fibrous histiocytomas, are a frequent STS histotype accounting for 14% of all adult STS \[[@B4-cancers-12-00362]\]. As a mesenchymal tumor, UPS can arise throughout the body, but 60% occur in the extremities \[[@B5-cancers-12-00362]\].

Generally, STS can be subdivided into two genetic groups. Several STS subtypes harbor specific genetic alterations such as translocations or activating mutations whereas the majority of STS displays complex karyotypes \[[@B6-cancers-12-00362],[@B7-cancers-12-00362],[@B8-cancers-12-00362]\]. Here, UPS belongs to those STS that show a high diversity of genomic alterations and oncogenic drivers. Recently published, the Cancer Genome Atlas Research Network characterized several alterations found in UPS samples \[[@B6-cancers-12-00362]\]. Interestingly, genomic profiling revealed a notable molecular similarity between myxofibrosarcomas and UPS although myxofibrosarcomas exhibit a completely different clinical behavior and rarely metastasize. However, in both, UPS as well as MFS, copy number alterations frequently affected VGLL3 and YAP1 which encode TEAD cofactors in the Hippo signaling pathway enhancing the proliferative activity. To date, the Hippo signaling pathway has been shown to play a crucial role in the development of several different malignancies and, therefore, presents an attractive treatment target where inhibitors are currently researched extensively \[[@B9-cancers-12-00362],[@B10-cancers-12-00362]\]. The low innate chemosensitivity of UPS towards the first-line chemotherapeutics Doxorubicin and Ifosfamide has promoted the development of novel treatment strategies including immunotherapeutic approaches \[[@B11-cancers-12-00362]\]. Published in 2017, a multi-center phase 2 trial (SARC028) assessed the safety and activity of pembrolizumab, an anti-PD-1 antibody, in ten patients with advanced UPS and presented encouraging results \[[@B12-cancers-12-00362]\]. Four of those ten UPS patients showed an objective response towards pembrolizumab. However, further studies are needed to determine the activity of anti-PD-1 antibodies in UPS patients with localized tumors as well as metastatic disease.

Within the heterogeneous group of STS, UPS belong to the more aggressive subtypes accompanied by a high risk of local recurrence and distant metastasis \[[@B13-cancers-12-00362],[@B14-cancers-12-00362],[@B15-cancers-12-00362],[@B16-cancers-12-00362],[@B17-cancers-12-00362]\]. The reported 5-year survival rates range from 60% to 76% \[[@B5-cancers-12-00362],[@B18-cancers-12-00362],[@B19-cancers-12-00362],[@B20-cancers-12-00362],[@B21-cancers-12-00362]\]. Those reporting studies have also determined several statistically significant indicators of survival which included tumor-related factors such as histologic grade, tumor size, and tumor depth. However, the prognostic impact of the surgical margin status remains controversial due to contradictory results. Furthermore, the influence of negative margin widths is still a subject of debate. However, it is important to define the optimal extent of surgery to ensure the best outcomes. Especially at the extremities, it is often difficult to attain wide clear margins due to functionally important structures.

The purpose of this study was to gain more insight into the clinical behavior of extremity UPS and to determine relevant prognostic factors reviewing our institutional experience. We focused particularly on the prognostic impact of treatment-related factors such as surgical margins, clear margin widths, and adjuvant radiotherapy on disease outcome.

2. Patients and Methods {#sec2-cancers-12-00362}
=======================

2.1. Patients {#sec2dot1-cancers-12-00362}
-------------

Between 1997 and 2017, 203 patients with primary UPS of the extremities were treated surgically with curative intent at our institution. We excluded patients presenting with simultaneous metastases to maintain a homogenous study population. We restricted analyses to 192 participants with full information available on the outcome, histology, and surgical margins at the initial procedure. Patient follow-up was obtained from our database, medical records, and patient correspondence. The study was approved by the ethics committee of the Medical Faculty of the Ruhr-University Bochum with the registration number 15-5411.

2.2. Treatment {#sec2dot2-cancers-12-00362}
--------------

The goal of surgical treatment for all patients was resection of the tumor with negative margins (R0) in curative intent. In epifascial lesions, a deep tumor-free margin of one fascial layer was intended. The indication for adjuvant radiation was given at the discretion of the interdisciplinary tumor board of either our institution or the referring institutions. Generally, all intermediate (G2) and high-grade (G3) tumors were recommended for further adjuvant radiation. After surgical resection, patients underwent a uniform follow-up regimen which included examinations (clinical, chest X-ray, contrast-enhanced MRIs) every three months in the first two years and every six months in the following three years, Several patients, especially individuals with recurrent tumors, had also consistent follow-up examinations beyond 5 years after tumor resection.

2.3. Histopathological Classification {#sec2dot3-cancers-12-00362}
-------------------------------------

All tumors were diagnosed and classified using the guidelines of the French Federation of Cancer Centers and the World Health Organization \[[@B22-cancers-12-00362],[@B23-cancers-12-00362]\]. All resected tumors were histopathologically analyzed by an experienced pathologist of our institution. The tumor surfaces were dyed with ink and the pathological specimen was fixated with formalin. The quality of the surgical margins, as well as the width of the negative margins, were assessed by the same pathologist.

2.4. Statistical Analysis {#sec2dot4-cancers-12-00362}
-------------------------

All patients were retrospectively analyzed regarding possible prognostic factors influencing survival. Overall survival (OS) was defined as the time period from the date of surgery for the primary disease to the date of death from any cause or the date of last follow-up assessment in living patients. Local recurrence-free survival (LRFS) has been defined as the time between the resection of the primary tumor and the first occurrence of local recurrence. In patients without local recurrence, the time period lasted from the date of the resection of the primary tumor to the date where the last follow-up assessment revealed no local recurrence. Survival analyses were performed via the Kaplan--Meier method including 95% confidence intervals (CIs) and log-rank test. To assess independent prognostic factors for OS and LRFS, we also have conducted multivariate analyses using the Cox proportional hazards model and the Wald test. Here, all prognostic factors that reached statistical significance in the univariate analyses with *p* \< 0.05 were included. For the statistical analysis, we have used the statistical program Stata (Version 11.2, StataCorp, College Station, TX, USA).

3. Results {#sec3-cancers-12-00362}
==========

3.1. Follow-Up and Patient Characteristics {#sec3dot1-cancers-12-00362}
------------------------------------------

The median follow-up time for the entire cohort was 5.1 years after diagnosis of the primary tumor. At the end of the follow-up time (cut-off date), 119 (62.0%) patients did not show any evidence of disease, In contrast, 11 patients (5.7%) were alive with the local recurrent disease and 13 (6.8%) were alive with distant metastases. Thirty-seven patients (19.3%) died because of their sarcoma disease and 12 patients (6.3%) died because of other causes ([Table 1](#cancers-12-00362-t001){ref-type="table"}).

The median age at the time of primary diagnosis was 64.5 years (range 18.3--89.9). There were 106 (55.2%) male and 86 (44.8%) female patients. The distribution of the histologic grading was G1 in 8 cases (4.2%), G2 in 69 (35.9%) and G3 in 115 (59.9%). In total, 35 patients (18.2%) had at least one local recurrence, whereas 33 (17.2%) patients had two or more local recurrences. During the follow-up time, 52 (27.1%) patients developed distant metastases.

3.2. Treatment Characteristics {#sec3dot2-cancers-12-00362}
------------------------------

Surgical treatment in one or more steps led to microscopically negative margins (R0) in 179 patients (93.2%), while 11 patients (5.7%) were left with microscopically positive margins (R1) and 2 (1.0%) with macroscopically positive margins (R2). In those patients with R1 or R2 margins, the tumors were too advanced and widespread for complete resection.

Generally, all patients with G2 and G3 tumors were recommended to receive further adjuvant radiation in their home areas. A total of 103 patients (53.6%) received adjuvant radiotherapy after resection of the primary tumor, with a median overall dose of 60.0 Gray (range: 25.0--70.0). Furthermore, 12 patients (6.2%) received preoperative radiotherapy while 12 patients (6.2%) were treated with adjuvant chemotherapy and only 4 patients (2.1%) with neoadjuvant chemotherapy.

3.3. Univariate Analysis of LRFS {#sec3dot3-cancers-12-00362}
--------------------------------

In the entire cohort, the 2-year and 5-year estimates of the LRFS rate were 74.1% (95% CI: 66.5--80.2) and 58.2% (95% CI: 49.3--66.0), respectively. The univariate analysis and comparison of patient- and tumor-related factors did not reveal any statistically significant findings. Patients under 60 years seemed to have a slightly better LRFS than the older patients, but the difference did not reach statistical significance ([Table 2](#cancers-12-00362-t002){ref-type="table"}). Female patients tended to have a better prognosis than the male patients regarding local failure, although this distribution failed to gain statistical significance either. Patients with tumors larger than 5cm displayed a 5-LRFS of 49.0% (95% CI: 37.1--59.8) whereas patients with smaller tumors had a 5-year LRFS of 70.0% (95% CI: 56.6--80.0) (*p* = 0.141). Moreover, patients with deep, subfascial tumors and tumors arising in the upper extremities also tended to have worse LRFS rates, however, statistical differences were not significant. Interestingly, treatment-related factors such as surgical margin status and radiotherapy were the only factors to reach statistical significance in univariate analysis for LRFS ([Table 2](#cancers-12-00362-t002){ref-type="table"}). Patients with R0 margins had a significantly more favorable LRFS than patients with R1 or R2 margins (2-year LRFS: R0 75.7 (67.9--81.8) vs. R1/R2 49.1% (16.7--75.3); *p* = 0.013) ([Figure 1](#cancers-12-00362-f001){ref-type="fig"}). Furthermore, we have also determined the impact of the negative margin widths within the subgroup of patients where tumors were resected with R0 margins. The quantitatively assessed negative margin widths were available for 140 of the 179 patients (78.2%) with R0-resected tumors. Here, the closest negative margin width was assessed as a potential treatment-related prognostic factor. However, univariate analysis could not reveal a significant difference between the patients groups: Patients with a negative margin width of ≤ 1mm had a 5-year LRFS of 64.1% (95% CI: 50.2--75.0) while patients with a negative margin width of \> 5mm displayed a 5-year LRFS of 68.2 (95% CI: 39.5--85.4). Regarding adjuvant radiotherapy, patients treated with radiation had a significantly prolonged LRFS compared with patients whose primary tumors were not treated with postoperative radiation (5-year LRFS: 67.6% (55.0--77.3) vs. 48.4% (36.0--59.7); *p* \< 0.001).

3.4. Univariate Analysis of OS {#sec3dot4-cancers-12-00362}
------------------------------

The 2-year and 5-year estimate of the OS rate were 86.8% (95% CI: 80.5--91.2) and 73.0% (95% CI: 64.5--79.7). Patients under 60 years tended to have a better OS than older patients (5-year OS: 79.9% (65.4--88.8) vs. 69.0% (57.9--77.6); *p* = 0.192). In accordance with our findings for LRFS, male patients also tended to have a slightly worse outcome than female patients. Among the tumor-related factors, histologic grade, and tumor size and depth had a prognostic significance on OS in univariate analysis ([Table 3](#cancers-12-00362-t003){ref-type="table"}). Patients with G2 tumors had more favorable prognoses than did patients with intermediate G3 lesions (5-year OS: G2 82.9% (68.7--91.1) vs. G3 67.9% (56.4--76.9); *p* = 0.017). In contrast to the findings for OS, tumor size and tumor depth reached statistical significance in univariate analysis. Primary tumors larger than 5 cm were associated with a significantly diminished outcome when compared with smaller tumors (5-year OS: 62.6% (50.9--72.2) vs. 89.1% (77.0--95.0); *p* = 0.002). Deep, subfascial localization also led to a significantly worse OS compared with epifascial lesions (5-year OS: 66.1% (55.6--74.6) vs. 91.7% (76.3--97.3); *p* = 0.003).

Regarding the treatment-related factors, surgical margin status and adjuvant radiotherapy reached prognostic significance. Patients with R0 margins had a 2-year OS rate of 87.2% (95% CI: 80.6--91.6), whereas patients with R1/R2 margins presented with a 2-year OS rate of 81.8% (95% CI: 44.7--95.1) *p* = 0.001) ([Figure 2](#cancers-12-00362-f002){ref-type="fig"}). Within the R0 subgroup, the clear margin width did not influence OS significantly. However, there seemed to be a tendency that wide negative margin widths were associated with a more favorable prognosis: Patients with negative margin widths ≤1 mm had a 5-year OS rate of 76.8% (95% CI: 64.6--85.3), whereas patients with 1-5 mm had a rate of 83.2% (95% CI: 59.4--93.7) and patients with \<5 mm 92.3% (95% CI: 56.6--98.9) (*p* = 0.070). Like findings for LRFS, adjuvant radiotherapy was associated with a significantly better OS (5-year OS: 82.8 (72.1--89.8) vs. 61.8 (48.2--72.8); *p* = 0.016).

3.5. Multivariate Analysis of LRFS {#sec3dot5-cancers-12-00362}
----------------------------------

Surgical margin status and adjuvant radiotherapy were associated with *p* \< 0.05 in the univariate analysis and, therefore, included in the Cox model to determine independent prognostic factors for LRFS ([Table 4](#cancers-12-00362-t004){ref-type="table"}). Here, positive margins were associated with a significantly increased risk of local recurrence (Hazard ratio \[HR\]: 3.08 (1.48--6.39); *p* = 0.003), while adjuvant radiotherapy improved local control (HR: 0.41 \[0.25--0.67); *p* \< 0.001). We also have analyzed age and gender, but they failed to reach statistical significance in multivariate analysis.

3.6. Multivariate Analysis of OS {#sec3dot6-cancers-12-00362}
--------------------------------

Significant and independent prognostic factors for the OS in the Cox model were histologic grade, tumor depth, surgical margin status, and adjuvant radiotherapy. Moreover, we have also included age and gender in the multivariate analysis. The HR for death was 2.65 (1.45--4.83) for G3 lesions (*p* = 0.001) and 4.65 (95% CI: 1.77--12.16) for subfascial tumors (*p* = 0.002). Regarding the treatment-related factors, positive margins were a strong negative predictive factor for OS (HR: 3.13 (1.54--6.38); *p* = 0.002). In accordance with our findings for the LRFS, adjuvant radiotherapy had a remarkably beneficial influence on OS with an HR of 0.50 \[0.28--0.89\] (*p* = 0.019). Notably, tumor size failed to reach statistical significance (*p* = 0.230) in multivariate analysis. Finally, age was found to be an independent prognostic factor of OS (*p* = 0.011)

4. Discussion {#sec4-cancers-12-00362}
=============

In the current study, we retrospectively analyzed the outcome of 192 patients with primary UPS of the extremities who underwent surgical treatment with curative intent. Most of the tumors displayed adverse biological features: They were high-grade (G3: 59.9%), subfascial localized (75.5%), and larger than 5 cm (64.0%). Although surgical treatment led to negative margins in 93.2% of all patients, 27.1% developed distant metastases during the median follow-up time of 5.1 years. The 5-year LRFS and OS rates were 58.2% and 73.0%, respectively. Notably, surgical margin status and adjuvant radiotherapy reached statistical significance as independent prognostic factors of both, LRFS and OS. Other independent predictive factors of OS were age, histologic grade, and tumor depth.

To date, there have been a few retrospective analyses that assessed the outcome of patients with UPS ([Table 5](#cancers-12-00362-t005){ref-type="table"}). Unfortunately, the results regarding the prognostic impact of surgical margins were inconsistent. In 2015, Dineen et al. from the MD Anderson Cancer Center in Houston determined the prognostic significance of surgical margins in 148 patients with sporadic and radiation-associated UPS of the extremities, the trunk and the head and neck area \[[@B5-cancers-12-00362]\]. Although they could find an association between R0 margins and local control (*p* = 0.019), surgical margin status did not influence survival in their analysis (*p* = 0.501). Recently published, Vodanovich et al. presented the largest retrospective analysis for UPS including 266 patients with tumors in the extremities and the trunk \[[@B18-cancers-12-00362]\]. Instead of the R classification Vodanovich et al. divided the quality of surgical margins into adequate margins including wide and radical resections and inadequate margins involving marginal and intralesional resections. In accordance with the findings of Dineen et al., inadequate margins had a statistically significant impact on local control but no on OS. Another large study was published by Le Doussal et al. in 1996 including 216 patients with extremity, trunk and head/neck UPS \[[@B21-cancers-12-00362]\]. However, only R2-resections were found to be of prognostic significance while microscopic margins did not alter the outcome. In 2019, Kamat et al. presented a study involving 55 patients with lower-extremity UPS \[[@B19-cancers-12-00362]\]. The 5-year disease-free survival rate for patients with positive margins was 33% compared with 63% for patients with negative margins (*p* = 0.03). Vice versa, they did not find an association between surgical margins and LRFS.

In our series, patients with microscopic negative margins had a significantly better LRFS and more favorable OS than patients with positive margins. To define the optimal surgical margin, we also analyzed the prognostic influence of the closest negative margin widths in 140 of the 179 patients (78.2%) with R0-resected tumors. Here, we could not detect a significant beneficial influence of wide negative margin widths. However, patients with wide negative margin widths tended to have a better OS: Patients categorized with negative margin widths \>5 mm had a 5-year OS rate of 92.3% whereas patients with negative margin widths ≤1 mm displayed a 5-year OS-rate of 76.8%. This finding would provide a more aggressive surgical approach in order to attain wider negative margins. Past studies of our institution which have determined the influence of negative margin widths in STS, in general, could not establish a relationship between margin widths and outcome \[[@B24-cancers-12-00362],[@B25-cancers-12-00362]\]. However, analyses of STS subsets such as angiosarcoma and dermatofibrosarcoma protuberans revealed that margin widths may indeed have an impact on specific entities \[[@B26-cancers-12-00362],[@B27-cancers-12-00362],[@B28-cancers-12-00362]\]. Therefore, it is crucial to analyze the entities separately and to assess the prognostic significance of treatment-related factors for every histologic subset specifically. Unfortunately, the low number of cases worldwide impede those efforts and decision-making is based on studies mixing all STS subsets together.

Adjuvant radiotherapy was another important treatment-related factor that had a remarkable impact on LRFS and OS in our series. Most of the studies focusing on UPS demonstrated that adjuvant radiotherapy improved significantly local control ([Table 5](#cancers-12-00362-t005){ref-type="table"}). However, none of the aforementioned studies could detect a beneficial impact of radiotherapy on OS. To date, there has been only one randomized, prospective trial that has assessed the impact of adjuvant radiation in STS patients with curative resectable tumors \[[@B29-cancers-12-00362]\]. Here, Beane et al. analyzed the outcome of 141 patients with extremity STS who underwent limb-sparing surgery. 70 of these 141 patients received adjuvant external beam radiation therapy while 71 patients were only treated with limb-sparing surgery. Although the 10-year OS rate was 77% for the non-radiated patients and 82% for the radiated patients, this statistical distribution did not gain statistical significance in their analysis (*p* = 0.22). However, the reason may be due to the relatively low proportion of patients with high-grade STS in their prospective study (29%). In a SEER-based analysis, Koshy et al. determined the effect of radiotherapy on OS among patients with STS of the extremities who underwent limb-sparing surgery \[[@B30-cancers-12-00362]\]. Notably, 59% of all patients had high-grade lesions and they could show that radiotherapy improved OS in patients with high-grade STS significantly. This is in line with our findings and may be caused by the high proportion of high-grade tumors (60.9%) in our patient population.

Finally, the reservation must be made that our series only included patients with primary UPS that were suitable for further surgical treatment with curative intent. We excluded patients with concurrent metastases at the time of primary diagnosis or patients who were treated in palliative intent. Hence, our findings are only applicable to the selected group of patients where further surgical treatment was possible and not to all patients with UPS. This implies a study selection bias that must be acknowledged.

5. Conclusions {#sec5-cancers-12-00362}
==============

In conclusion, this study could underscore the independent prognostic significance of surgical margins for LRFS and OS. It is noteworthy that only the quality of surgical margins, but not the negative margin width had a prognostic influence. Moreover, adjuvant radiotherapy had a similarly strong impact on local control as well as survival which may be due to the high proportion of high-grade tumors in our series. With respect to the currently available data from the present and previous studies on UPS, treatment efforts should aim at limb-sparing resections when feasible with negative margins involving radiotherapy to ensure optimal local control and survival.
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cancers-12-00362-t001_Table 1

###### 

Patient and disease characteristics.

  --------------------------------------------------------
  Characteristic                       *N*   \% of Total
  ------------------------------------ ----- -------------
  Total                                192   

  Age (years)                                

  ≤60                                  72    37.5

  \>60                                 120   62.5

  Sex                                        

  Female                               86    44.8

  Male                                 106   55.2

  Tumor size                                 

  ≤5 cm                                69    36.0

  \>5 cm                               123   64.0

  Tumor depth                                

  Epifascial                           47    24.5

  Subfascial                           145   75.5

  Tumor site                                 

  Upper extremity                      66    34.4

  Lower extremity                      126   65.6

  Grading                                    

  G1                                   8     4.2

  G2                                   69    35.9

  G3                                   115   59.9

  Margin status\                             
  (Primary tumor)                            

  R0                                   179   93.2

  R1                                   11    5.7

  R2                                   2     1.0

  Adjuvant radiotherapy\                     
  (Primary tumor)                            

  No                                   89    46.4

  Yes                                  103   53.6

  Neoadjuvant radiotherapy\                  
  (Primary tumor)                            

  No                                   180   93.8

  Yes                                  12    6.2

  Adjuvant chemotherapy\                     
  (Primary tumor)                            

  No                                   180   93.8

  Yes                                  12    6.2

  Neoadjuvant chemotherapy\                  
  (Primary tumor)                            

  No                                   188   97.9

  Yes                                  4     2.1

  Status                                     

  No evidence of disease               119   62.0

  Alive with local recurrent disease   11    5.7

  Alive with distant metastases        13    6.8

  Died due to UPS                      37    19.3

  Died due to other causes             12    6.3
  --------------------------------------------------------

cancers-12-00362-t002_Table 2

###### 

Results of the univariate analyses to determine factors predictive of LRFS.

  ----------------------------------------------------------------------------------------------------------------------------------------
  Characteristic              *N*   No. of Local Recurrence   1-Year LRFS\        2-Year LRFS\        5-Year LRFS\        *p* (Log-Rank)
                                                              (95%-CI)            (95%-CI)            (95%-CI)            
  --------------------------- ----- ------------------------- ------------------- ------------------- ------------------- ----------------
  All patients                192   68                        84.4 (78.1--89.0)   74.1 (66.5--80.2)   58.2 (49.3--66.0)   

  Age (years)                                                                                                             

  ≤60                         72    25                        90.8 (80.7--95.8)   72.0 (58.7--81.6)   62.4 (48.4--73.5)   

  \>60                        120   43                        80.5 (71.6--86.8)   76.0 (66.4--83.1)   55.3 (43.4--65.7)   0.371

  Sex                                                                                                                     

  Female                      86    27                        88.2 (78.5--93.7)   81.9 (70.8--89.1)   63.3 (49.6--74.2)   

  Male                        106   41                        81.5 (72.3--88.0)   67.9 (57.0--76.6)   53.9 (41.9--64.5)   0.194

  Tumor size                                                                                                              

  ≤5 cm                       69    22                        84.0 (72.3--91.1)   75.4 (62.5--84.4)   70.0 (56.6--80.0)   

  \>5 cm                      123   46                        84.6 (76.3--90.1)   72.9 (62.8--80.7)   49.0 (37.1--59.8)   0.141

  Tumor depth                                                                                                             

  Epifascial                  47    17                        86.6 (72.6--93.8)   76.5 (60.7--86.7)   65.4 (48.3--78.0)   

  Subfascial                  145   51                        83.6 (75.9--89.0)   73.2 (64.1--80.3)   55.5 (44.9--64.8)   0.708

  Tumor site                                                                                                              

  Upper extremity             66    31                        84.3 (72.8--91.2)   73.6 (60.4--83.0)   49.8 (35.1--62.8)   

  Lower extremity             126   37                        84.4 (76.1--90.0)   74.3 (64.5--81.8)   63.6 (52.6--72.7)   0.169

  Grading                                                                                                                 

  G1                          8     4                         87.5 (38.7--98.1)   87.5 (38.7--98.1)   72.9 (27.6--92.5)   

  G2                          69    31                        84.8 (73.5--91.5)   74.7 (62.1--83.7)   55.0 (41.3--66.7)   

  G3                          115   33                        83.9 (75.0--89.8)   72.6 (62.0--80.7)   60.4 (47.9--70.8)   0.799 \*

  Margin status\                                                                                                          
  (Primary tumor)                                                                                                         

  R0                          179   61                        85.9 (79.5--90.4)   75.7 (67.9--81.8)   60.9 (51.8--68.7)   

  R1/R2                       13    7                         61.4 (26.6--83.5)   49.1 (16.7--75.3)   (--)                0.013

  Negative margin width                                                                                                   

  ≤1 mm                       88    26                        90.2 (81.3--95.0)   78.2 (66.7--86.1)   64.1 (50.2--75.0)   

  \>1 mm and ≤5 mm            36    5                         96.3 (76.5--99.5)   86.9 (64.3--95.6)   76.6 (52.1--89.7)   

  \>5 mm                      16    5                         75.0 (46.3--89.8)   75.0 (46.3--89.8)   68.2 (39.5--85.4)   0.272 \*

  Adjuvant radiotherapy\                                                                                                  
  (Primary tumor)                                                                                                         

  No                          89    44                        79.3 (68.8--86.6)   66.5 (54.7--75.9)   48.4 (36.0--59.7)   

  Yes                         103   24                        89.0 (80.5--93.9)   81.1 (70.8--88.0)   67.6 (55.0--77.3)   \<0.001

  Neoadjuvant radiotherapy\                                                                                               
  (Primary tumor)                                                                                                         

  No                          180   63                        83.9 (77.2--88.7)   74.9 (67.1--81.1)   58.3 (49.1--66.5)   

  Yes                         12    5                         91.7 (53.9--98.8)   66.7 (33.7--86.0)   57.1 (25.4--79.6)   0.953

  Adjuvant chemotherapy\                                                                                                  
  (Primary tumor)                                                                                                         

  No                          180   62                        80.5 (68.2--88.5)   71.1 (57.6--81.0)   63.2 (48.1--75.0)   

  Yes                         12    6                         86.3 (78.3--91.5)   75.3 (65.5--82.7)   56.0 (44.7--65.8)   0.656

  Neoadjuvant chemotherapy\                                                                                               
  (Primary tumor)                                                                                                         

  No                          188   66                        84.0 (77.6--88.8)   74.1 (66.4--80.3)   58.4 (49.4--66.4)   

  Yes                         4     2                         100 (--)            75.0 (12.8--96.1)   50.0 (5.8--84.5)    \-
  ----------------------------------------------------------------------------------------------------------------------------------------

\* global log-rank test for trend of survivor functions. LRFS, local recurrence-free survival; CI, confidence interval.

cancers-12-00362-t003_Table 3

###### 

Results of the univariate analyses to determine factors predictive of OS.

  ----------------------------------------------------------------------------------------------------------------------------------
  Characteristic                  *N*   No. of Deaths   1-Year OS\          2-Year OS\          5-Year OS\          *P* (Log-Rank)
                                                        (95%-CI)            (95%-CI)            (95%-CI)            
  ------------------------------- ----- --------------- ------------------- ------------------- ------------------- ----------------
  All patients                    192   50              96.5 (92.4--98.4)   86.8 (80.5--91.2)   73.0 (64.5--79.7)   

  Age (years)                                                                                                       

  ≤60                             72    16              100 (--)            91.2 (80.1--96.3)   79.9 (65.4--88.8)   

  \>60                            120   34              94.4 (87.9--97.4)   84.1 (75.4--90.0)   69.0 (57.9--77.6)   0.192

  Sex                                                                                                               

  Female                          86    20              100 (--)            92.5 (82.9--96.8)   71.9 (57.9--81.9)   

  Male                            106   30              93.9 (86.9--97.2)   82.5 (72.9--88.9)   74.1 (63.1--82.3)   0.274

  Tumor size                                                                                                        

  ≤5 cm                           69    11              98.5 (89.6--99.8)   93.4 (83.2--97.5)   89.1 (77.0--95.0)   

  \>5 cm                          123   39              95.4 (89.2--98.0)   82.9 (73.8--89.0)   62.6 (50.9--72.2)   0.002

  Tumor depth                                                                                                       

  Epifascial                      47    5               100 (--)            97.5 (83.5--99.6)   91.7 (76.3--97.3)   

  Subfascial                      145   45              95.3 (89.8--97.8)   83.0 (74.9--88.7)   66.1 (55.6--74.6)   0.003

  Tumor site                                                                                                        

  Upper extremity                 66    20              96.7 (87.4--99.2)   86.4 (74.6--93.0)   69.9 (55.2--80.6)   

  Lower extremity                 126   30              96.4 (90.8--98.6)   87.1 (78.7--92.3)   75.0 (64.1--82.9)   0.561

  Grading                                                                                                           

  G1                              8     4               100 (--)            87.5 (38.7--98.1)   60.0 (19.5--85.2)   

  G2                              69    14              100 (--)            100 (--)            82.9 (68.7--91.1)   

  G3                              115   32              93.9 (86.9--97.2)   77.8 (67.6--85.1)   67.9 (56.4--76.9)   0.017 \*

  Margin status (Primary tumor)                                                                                     

  R0                              179   44              96.9 (92.6--98.7)   87.2 (80.6--91.6)   75.5 (66.9--82.2)   

  R1/R2                           13    6               90.9 (50.8--98.7)   81.8 (44.7--95.1)   38.4 (10.3--66.8)   0.001

  Negative margin width                                                                                             

  ≤1 mm                           88    22              96.3 (89.1--98.8)   84.0 (73.5--90.6)   76.8 (64.6--85.3)   

  \>1 mm and ≤5 mm                36    4               93.2 (75.4--98.3)   89.6 (71.1--96.5)   83.2 (59.4--93.7)   

  \>5 mm                          16    1               100 (--)            100 (--)            92.3 (56.6--98.9)   0.070 \*

  Adjuvant radiotherapy\                                                                                            
  (Primary tumor)                                                                                                   

  No                              89    31              96.3 (88.9--98.8)   81.7 (71.0--88.8)   61.8 (48.2--72.8)   

  Yes                             103   19              96.7 (90.2--98.9)   91.7 (83.3--96.0)   82.8 (72.1--89.8)   0.016

  Neoadjuvant radiotherapy\                                                                                         
  (Primary tumor)                                                                                                   

  No                              180   46              96.2 (91.8--98.3)   86.5 (79.8--91.1)   73.8 (65.0--80.7)   

  Yes                             12    4               100 (--)            91.7 (53.9--98.8)   66.7 (33.7--86.0)   0.997

  Adjuvant chemotherapy\                                                                                            
  (Primary tumor)                                                                                                   

  No                              180   43              96.4 (90.7--98.6)   86.6 (78.3--91.8)   73.9 (63.3--81.8)   

  Yes                             12    7               96.7 (87.4--99.2)   87.4 (75.3--93.8)   72.0 (56.7--82.7)   0.885

  Neoadjuvant chemotherapy\                                                                                         
  (Primary tumor)                                                                                                   

  No                              188   48              96.4 (92.2--98.4)   87.2 (80.8--91.5)   73.8 (65.2--80.5)   

  Yes                             4     2               100 (--)            75.0 (12.8--96.1)   50.0 (5.8--84.5)    \-
  ----------------------------------------------------------------------------------------------------------------------------------

\* global log-rank test for trend of survivor functions. OS, overall survival; CI, confidence interval.
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###### 

Results of multivariate analysis on LRFS and OS according to the Cox proportional hazard model.

  Category (Reference)                 LRFS                OS                             
  ------------------------------------ ------------------- --------- -------------------- -------
  Depth: subfascial (vs. epifascial)   \-                  \-        4.65 (1.77--12.16)   0.002
  Size: \>5 cm (vs. ≤5 cm)             \-                  \-        1.63 (0.73--3.63)    0.230
  Grade: G3 (vs. G1)                   \-                  \-        2.65 (1.45--4.83)    0.001
  Margin status: R1/R2 (vs. R0)        3.08 (1.48--6.39)   0.003     3.13 (1.54--6.38)    0.002
  Adjuvant radiation: Yes (vs. no)     0.41 (0.25--0.67)   \<0.001   0.50 (0.28--0.89)    0.019
  Sex: Male (vs. female)               1.41 (0.86--2.33)   0.175     1.04 (0.53--2.02)    0.916
  Age: \>60 (vs. ≤60)                  1.23 (0.76--2.00)   0.396     2.32 (1.21--4.44)    0.011

LRFS, local recurrence-free survival; OS, overall survival; MFS; CI, confidence interval. Factors that did not reach statistical significance (*p* \< 0.05) in the univariate analysis were not included in the multivariate analysis.
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###### 

Overview of retrospective analyses on undifferentiated pleomorphic sarcomas (UPS).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Year)       *N*       Site                          Median FU\   5-LRFS\   5-OS\    Independent Prognostic Effect of Microscopic Margins on   Independent Prognostic Effect of Adjuvant Radiotherapy on        
                                                              (Years)      (%)       (%)                                                                                                                                 
  ------------------- --------- ----------------------------- ------------ --------- -------- --------------------------------------------------------- ----------------------------------------------------------- ---- ----
  Present study       192       Extremity                     5.1          58        73       \+                                                        \+                                                          \+   \+

  Kamat (2019)        55        Lower Extremity               4.5          60        68       −                                                         \+                                                          \+   −

  Vasileios (2012)    61        Extremity                     4.3          NA        67       −                                                         −                                                           −    −

  Dineen (2015)       148 ^a^   Extremity, Trunk, Head/Neck   NA           75        76 ^b^   \+                                                        −                                                           −    −

  Vodanovich (2018)   266       Extremity, Trunk, Head/Neck   7.0          85        60       \+                                                        −                                                           −    −

  Le Doussal (1996)   216       Extremity, Trunk, Head/Neck   3.5          63        70 ^b^   −                                                         −                                                           \+   −
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FU, follow-up; 5-LRFS, local recurrence-free survival rate at 5 years; 5-OS, overall survival at 5 years; 5-DSS, disease-specific survival at 5 years; NA, data not available. ^a^ matched cohort analysis; ^b^ value for 5-year DSS.
